As organisations concerned with the current and future wellbeing of our rapidly ageing society, the International Longevity Centre – UK (ILC-UK) and the International Federation on Ageing (IFA) have conducted a great deal of work on the burden of pneumococcal disease across the life-course.

We believe that the UK’s immunisation programme over recent years has been very successful in reducing incidences of Invasive Pneumococcal Disease (IPD), a major cause of death globally.

However, in October 2017 the Joint Committee on Vaccination and Immunisation (JCVI) suggested that the childhood vaccination for pneumococcal disease should move from a 2+1 schedule (two initial doses and a follow-up dose) to a 1+1 schedule (one initial dose and a follow-up).

We were concerned to hear from the JCVI’s reports that “moving to a 1+1 schedule might increase IPD cases in infants because of loss of direct protection, and in older adults because of a reduction in herd immunity as a result of less protection against carriage in infants after a single dose.”

We would welcome more detailed research into the potential increase in cases of invasive pneumococcal disease in children and adults that might occur from a change to the pneumococcal immunisation programme, to a ‘1 + 1’ schedule.

Given the potential risks of this decision, we would urge a fuller consultation on proposed changes to the pneumococcal immunisation programme. Perhaps an expert sub-committee of JCVI could be convened to review the evidence before a final decision is made.

Finally, to declare an interest, ILC-UK’s work on immunisation has been financially supported (through non-restricted educational grants) by a range of pharmaceutical companies who may have an interest in this area including SPMSD, Eli Lilly, and Pfizer and the IFA’s work on immunisation has been supported similarly by Pfizer and GSK through unrestricted educational grants.


David Sinclair                           Jane Barratt
Director                                  Secretary General
ILC-UK                                   International Federation on Ageing


The International Longevity Centre – UK (ILC-UK) and Just Group have analysed the submissions and created a shortlist to take forward that helps deal with ageing issues such as cognitive decline, failing physical health, loneliness and digital exclusion.

We are looking for an experienced, flexible and proactive candidate to support the Senior Management Team in managing the financials of the organisation.

The ILC-UK has launched a Commission Inquiry on Health and Wellbeing Innovation, supported by Audley Retirement Villages and EY.

However, the analysis also finds the higher the proportion of over 70s in a local population, the higher the rate of productivity growth

Just and ILC-UK ‘Innovating for Ageing’ project calls for submissions on problems relating to consumer vulnerability

Life expectancy and health outcomes worsen the more deprived an area or population is, new research from Cass Business School has found.